B-and T-lymphocyte attenuator (BTLA) is an inhibitory receptor of the CD28 superfamily that negatively regulates the immune response in synergy with the CTLA-4/B7-1(B7-2) and PD-1/PDL1(PD-L2) inhibitory pathways. 1-3 BTLA interacts with herpesvirus entry mediator (HVEM), which belongs to the tumor necrosis factor receptor superfamily. [4] [5] [6] Crosslinking of BTLA by HVEM induces tyrosine phosphorylation and recruitment of SHP-1 and SHP-2 by the immunoreceptor tyrosine-based inhibition motifs, resulting in inhibition of T-cell proliferation and cytokine production. 4, 5, 7 The latter effect includes down-regulation of interferon γ, interleukin (IL)-2, IL-4, and IL-10, indicating that BTLA-signals influence T H 1 and T H 2 differentiation. [8] [9] [10] Expression of HVEM by regulatory T cells suppresses the function of BTLA+ effector T cells. 11 In addition to binding to BTLA, HVEM interacts with the T-cell receptor LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes), CD160, and lymphotoxin-α. HVEM-knockout mice have higher T-cell activation, 12 indicating that the inhibitory function of HVEM is dominant, although stimulation of LIGHT by HVEM induces a positive signal. 13 Deficiencies in BTLA or HVEM result in similar phenotypes, in which T-cell hyperactivation leads to inflammation. 14 Altogether, previous data suggest that dysfunction of the BTLA-HVEM pathway is suspected to have a role in the pathogenesis of various autoimmune, neoplastic, and inflammatory diseases. 4, 15, 16 Mouse naive B cells express high levels of BTLA. 4 BTLA expression is also significant in mouse thymocytes during positive selection, whereas it is lower in naive T cells, and it increases during T-cell receptor ligation. 17 In humans,
B-and T-lymphocyte attenuator (BTLA) is a lymphoid receptor that inhibits lymphocyte activation on interaction with its ligand, herpesvirus entry mediator (HVEM). We developed monoclonal antibodies against BTLA and HVEM to study their expression using immunohistochemical and flow cytometric analyses in human tissues. In reactive lymph nodes, they were both expressed in interfollicular T cells and in B cells from mantle and marginal zones. Within germinal centers, B cells were negative, whereas T follicular helper (TFH) cells were BTLA+ and follicular dendritic cells were HVEM+. BTLA was strongly expressed in chronic lymphocytic leukemia/ small lymphocytic lymphoma (B-CLL/SLL, 19 of 19 positive) when compared with other small B-cell lymphomas, including follicular lymphoma (0 of 24 positive), mantle cell lymphoma (0 of 10 positive), and marginal zone lymphoma (0 of 5 positive). Our results suggest that down-regulation of the BTLA-HVEM pathway may be involved in germinal center B-cell activation. The specific high expression of BTLA in B-CLL/SLL represents a new potential diagnostic tool. The BTLA positivity of TFH cells may be a basis for designing future immunotherapies.
B-and T-lymphocyte attenuator (BTLA) is an inhibitory receptor of the CD28 superfamily that negatively regulates the immune response in synergy with the CTLA-4/B7-1(B7-2) and PD-1/PDL1(PD-L2) inhibitory pathways. [1] [2] [3] BTLA interacts with herpesvirus entry mediator (HVEM), which belongs to the tumor necrosis factor receptor superfamily. [4] [5] [6] Crosslinking of BTLA by HVEM induces tyrosine phosphorylation and recruitment of SHP-1 and SHP-2 by the immunoreceptor tyrosine-based inhibition motifs, resulting in inhibition of T-cell proliferation and cytokine production. 4, 5, 7 The latter effect includes down-regulation of interferon γ, interleukin (IL)-2, IL-4, and IL-10, indicating that BTLA-signals influence T H 1 and T H 2 differentiation. [8] [9] [10] Expression of HVEM by regulatory T cells suppresses the function of BTLA+ effector T cells. 11 In addition to binding to BTLA, HVEM interacts with the T-cell receptor LIGHT (lymphotoxin-like, exhibits inducible expression, and competes with herpes simplex virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes), CD160, and lymphotoxin-α. HVEM-knockout mice have higher T-cell activation, 12 indicating that the inhibitory function of HVEM is dominant, although stimulation of LIGHT by HVEM induces a positive signal. 13 Deficiencies in BTLA or HVEM result in similar phenotypes, in which T-cell hyperactivation leads to inflammation. 14 Altogether, previous data suggest that dysfunction of the BTLA-HVEM pathway is suspected to have a role in the pathogenesis of various autoimmune, neoplastic, and inflammatory diseases. 4, 15, 16 Mouse naive B cells express high levels of BTLA. 4 BTLA expression is also significant in mouse thymocytes during positive selection, whereas it is lower in naive T cells, and it increases during T-cell receptor ligation. 17 In humans, BTLA expression has been described in lymphocytes from blood and pleural fluid, 10 but there is no information in the literature about the distribution of BTLA and its ligands in human lymphoid tissues.
By using a combination of immunohistochemical analysis and flow cytometric analysis (FCM), we studied the in vivo distribution of BTLA within human normal lymph nodes and malignant lymphomas. We show that the highest levels of BTLA expression are found in normal T follicular helper (TFH) cells and in neoplastic B chronic lymphocytic leukemia (B-CLL) cells.
Materials and Methods

Generation of Anti-BTLA and Anti-HVEM Monoclonal Antibodies
Monoclonal antibodies (mAbs) recognizing BTLA (clones 7.1 and 8.2) and HVEM (clones 6.11 and 10.3) were generated by immunization of balb-c mice with the respective recombinant human Fc-IgG 1 fusion proteins. Spleen cells were fused with X-63 myeloma cells and cloned according to already described procedures. 18 Hybridoma supernatants were screened for staining of transfected cells and for lack of reactivity with untransfected cells. The BTLA and HVEM hybridomas have been described elsewhere (N. Seriari, MD, PhD, et al, unpublished data, 2008). BTLA and HVEM mAbs were shown to be able to compete for BTLA-HVEM binding (data not shown). The BTLA-8.2 and HVEM-10.3 clones were chosen for further immunohistochemical analysis based on their capacity to stain frozen sections, whereas the BTLA-7.1 and HVEM-6.11 clones were used for FCM experiments.
Tissue Sampling
Biopsy samples from patients who had given informed consent were analyzed using immunohistochemical analysis on frozen tissue sections, including 25 cases of Hodgkin lymphoma (HL) and 52 cases of non-Hodgkin lymphoma (NHL). Low-and high-grade B-cell NHLs (n = 47) and T-cell NHLs (n = 5) were classified according to the World Health Organization classification 19 zTable 1z. Diagnosis was based on morphologic examination and immunophenotyping. The staining panel included at least CD20 and CD3 in conjunction with follicular dendritic cell (FDC) markers (CD23 and CNA42) and Reed-Sternberg cell markers (CD30 and CD15). A control group of nonneoplastic tissues from reactive lymphadenitis (n = 13) was also tested. All of these lymphadenitis cases showed common features of hyperplasia that mainly involved follicular areas and more slightly paracortical areas. Fresh tissue samples were obtained and stored at -70°C until use.
Immunohistochemical Analysis
Single Immunohistochemical Staining
BTLA and HVEM immunostainings were performed on total frozen sections as previously described. 20 The final dilution for BTLA and HVEM mAbs was 10 µg/mL. Positive control samples were sections of reactive lymph nodes. Negative control samples were prepared by omitting the primary mAb. Immunostaining in a given cell population was evaluated as negative (0) if fewer than 10% of the cells were positive, 1+ if 10% to 50% of the cells were positive, 2+ if more than 50% to 75% of the cells were positive, and 3+ if more than 75% of the cells were positive.
Serial and Double Immunohistochemical Staining
For serial and double immunohistochemical staining, we selected mAbs directed against CD3 (DakoCytomation, Carpinteria, CA) for T cells and CD23 (Lab Vision, Fremont, CA) for FDCs. Serial frozen sections from reactive lymph nodes were alternatively stained with CD23 and HVEM using the same procedure as for single staining. Fluorescent double BTLA/CD3 or HVEM/CD23 immunostainings were performed on frozen sections from reactive lymph nodes. For each double staining, primary antibodies were incubated overnight at room temperature. The secondary antibodies were antimouse Alexa Fluor 488 and antirabbit Alexa Fluor 594 (Invitrogen, Carlsbad, CA), respectively. They were incubated for 30 minutes. Slides were then counterstained with 4′,6′-diamidino-2-phenylindole (DAPI) and analyzed using a Zeiss confocal microscope (Carl Zeiss Microimaging, Oberkochen, Germany).
FCM Analysis
Fresh blood CLL cells or lymphoma cells teased from lymph nodes were collected from 24 patients who had given informed consent. For blood samples, Lymphoprep (AxisShield PoC AS, Oslo, Norway)-separated mononuclear cells were washed and resuspended in RPMI 1640 (Invitrogen, Eugene, OR) supplemented with 10% heat-inactivated fetal bovine serum (Lonza, Verviers, Belgium). For lymph node cells, mononuclear cells were obtained by crushing fresh tissue samples in RPMI 1640 supplemented with 10% heatinactivated fetal bovine serum. To facilitate cell surface staining, mAbs anti-PD1 (clone 3.1) and BTLA (clone 7.1) were stained using a commercially available kit ( 
Results
Immunohistochemical Analysis Shows Widespread BTLA Positivity in Reactive Lymph Nodes, Except in Germinal Center B Cells
In reactive lymph node samples displaying features of follicular hyperplasia, BTLA immunostaining was widespread.
The strongest signals were observed in mantle zone small lymphocytes. Numerous BTLA+ cells were also found in the interfollicular T-cell areas. Within germinal centers (GCs), large centroblasts were BTLA-, whereas scattered small lymphocytes with the distribution of follicular T cells were intensely positive zImage 1Az and zImage 1Bz. When compared with BTLA-stained sections, serial sections stained with CD3 exhibited an almost similar pattern of positivity within GCs. Combined CD-/BTLA immunostaining confirmed that most BTLA+ cells within the GCs were CD3+ zImage 1Cz, whereas within the mantle zone, virtually 100% of the cell population was simultaneously CD3-and BTLA+.
Among Normal B Cells, the Highest BTLA Expression Is Found in Naive B Cells
To confirm the immunohistochemical profile, fresh cells purified from reactive lymph node were analyzed by FCM. Among CD20+ cells, IgD+/CD38-naive B cells exhibited the highest levels of BTLA expression, slightly higher than that of IgD-/CD38-memory B cells. In contrast, CD38+/ IgD-GC B cells were negative zImage 2z.
Among Normal T Cells, High Levels of BTLA Expression Are Found in TFH Cells
To confirm the strong staining observed with immunohistochemical analysis, fresh cells purified from reactive lymph nodes were analyzed by FCM. Among CD3+/CD4+ T cells, ICOS+/CXCR5+ cells exhibited high levels of PD1 and BTLA expression compared with ICOS-/CXCR5-cells zImage 3z.
Among B-NHL Subtypes, High BTLA Expression Is Specific for B-SLL/CLL
BTLA distribution among lymphoma samples is summarized in Table 1 . Among nodal B-cell NHLs, small lymphocytic lymphoma (B-SLL) was the only subtype in which the malignant B cells exhibited strong immunohistochemical BTLA positivity in all cases (8/8) zImage 1Dz. Other subtypes of small B-cell NHLs exhibited no or faint BTLA positivity among the malignant cell population, including mantle cell lymphoma (MCL; 0/7) zImage 1Ez, follicular lymphoma (FL; 0/16) zImage 1Fz, marginal zone lymphoma (MZL; 0/3), and Burkitt lymphoma (0/2). All B-NHL samples contained a variable proportion of BTLA-labeled reactive T cells (Image 1F). A minority of diffuse large cell lymphoma cases (3/11) were weakly BTLA+ zImage 1Gz. Our series included 2 cases of T cell-rich large B-cell lymphoma and 2 cases of nodular lymphocyte predominant HL. In both diseases, normal T cells showed a similar pattern of strong positivity for BTLA (data not shown). This finding suggests that there is no distinctive feature that could help to zImage 1z Immunohistochemical patterns of B-and T-lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM) expression in reactive lymph nodes and lymphomas. A, B, and C, In reactive lymph nodes, BTLA staining was mainly observed in interfollicular T-cell areas (A, white asterisk), but the strongest positivity was located in the mantle zone (A, arrow), whereas only a few positive small lymphocytes were scattered within the germinal center (GC) (A, black asterisk). B, High-power view of area in A highlights the intense staining of the mantle zone (arrow) compared with the GC (asterisk). C, CD3/BTLA dual fluorescence immunostaining in the same area as B shows a few CD3+ T cells scattered within the GC (red staining), whereas BTLA+ lymphocytes (green staining) are mainly located within the mantle zone (asterisk). Within the GC, most BTLA+ cells appear also CD3+ (colocalization of red and green signals, arrows). D, Strong BTLA positivity of small lymphocytic lymphoma/ chronic lymphocytic leukemia (SLL/CLL) in virtually 100% of neoplastic cells, whereas a small capillary vessel appears negative (arrow). E, In a case of mantle cell lymphoma, only faint positivity can be detected in a minority of lymphoma cells (arrow). distinguish T cell-rich large B-cell lymphoma from nodular lymphocyte predominant HL based on this criterion. FCM analysis performed on fresh lymphoma cells purified from lymph nodes confirmed that the highest levels of BTLA expression were found in CLL neoplastic B cells but not in other small B-cell NHLs. The average mean ± SD fluorescence intensity for BTLA among the 11 CLL cases analyzed was 2,634 (± 560), whereas it was 928 (± 490), 494 (± 217), and 540 (± 296) in FL cases (n = 8), MCL cases (n = 3) and MZL cases (n = 2), respectively zFigure 1z. 
BTLA Is Expressed in Neoplastic T Cells From T-NHL but Not From HL
The 5 T-NHL samples analyzed displayed BTLA positivity, including "unspecified" peripheral T-NHL and angioimmunoblastic T-NHL zImage 1Hz. BTLA positivity was detected in variable amounts of reactive small T cells from most HL cases, including classical HL and lymphocyte predominant HL. Reed-Sternberg cells and variants were negative zImage 1Iz.
HVEM Is Expressed in FDC but Not in GC Cells
In hyperplastic lymph nodes (n = 13), HVEM was strongly expressed in mantle zone B cells and to a lesser extent in T cells within interfollicular areas zImage 1Jz. Within GCs, B lymphocytes were HVEM-, whereas FDCs were HVEM+ (Image 1J) and zImage 1Kz. Immunohistochemical positivity was also observed in small vessels and on microgranulomas present in 2 cases.
HVEM Is Constantly Expressed in B-SLL/CLL
Among B-NHLs, strong HVEM immunostaining was observed in the 8 SLL cases analyzed zImage 1Lz, whereas HVEM expression was weak in occasional other small B-cell subtypes, including FL, MCL, and MZL.
Discussion
The present report describes the distribution of BTLA in a large series of human lymphomas using new anti-BTLA mAbs available for immunohistochemical analysis and FCM. Although BTLA expression has been described in mice and human blood cells, 10 there are no data in the literature about the immunohistochemical expression of BTLA in human lymphoid tissues. We report herein that BTLA was highly expressed on naive B cells of the mantle zone and to a lesser extent on memory B cells of the marginal zone. In contrast, GC B cells were uniformly negative.
The extinction of BTLA in GC B cells may be involved in the GC activation process and in the triggering of the rapid cell proliferation that occurs in the GC dark zone. Of note, BTLA was also absent in GC B cells within the light zone, which is in accordance with recent challenging multiphoton microscopy observations that GC B-cell division occurs in the light zone and in the dark zone as well. 21, 22 It also supports microarray results 23 suggesting that phenotypes of GC B cells in these 2 areas may not be as different as previously thought.
Among T lymphocytes, we showed that the highest level of BTLA expression is found in CD4+/CXCR5+/ ICOS+/PD1+ cells, a phenotypic profile specific for TFH cells. [24] [25] [26] [27] [28] TFH cells also express high levels of SAP, CD84, CD229 (Ly9), Fyn, bcl-6, IL-21, and CXCL13, although this expression is heterogeneous. [24] [25] [26] High expression of ICOS is supposed to better reflect the effector function of TFH cells, namely their ability to induce immunoglobulin secretion from B cells, because it is directly correlated to the amount of IL-10 produced. 29, 30 Because the expression levels of ICOS and BTLA were tightly correlated, high levels of BTLA may be an additional characteristic defining the subgroup of effector TFH cells.
We showed that TFH cells simultaneously express high levels of PD1 and BTLA inhibitory receptors, which suggests that TFH cells specially require strong negative regulation. In fact, inappropriate signals from TFH cells are potentially dangerous because they contribute to the pathogenesis of autoimmune diseases. For example, IL-21 is overexpressed in the BXSB murine lupus model, 31 and humans with systemic lupus erythematosus have an increased frequency of ICOS+/CD4+ T cells in their peripheral blood. 32 Thus, it is possible that both BTLA and PD1 inhibitory pathways are necessary for efficient control of TFH cell activity. This hypothesis is also in accordance with the susceptibility to experimental autoimmune encephalomyelitis observed in BTLA-deficient mice. 1 By using immunohistochemical analysis, a method that closely reflects in vivo conditions, we observed strong immunostaining of the BTLA ligand HVEM in the mantle zone and marginal zone B cells, whereas GC B cells were negative. These data confirm previous in vitro data that suggested high HVEM expression in naive and memory human B cells, whereas it was undetectable in GC B cells. 4 Moreover, we provide the additional information that HVEM is highly expressed in GC FDCs. It is known that T-cell activation is stimulated by HVEM binding to LIGHT, whereas it is inhibited by HVEM binding to BTLA or CD160. 33 In view of our results, it is thus possible that FDCs use HVEM signals to inhibit TFH cells.
We herein report high BTLA expression in B-CLL when compared with other B-cell lymphomas. Of note, we previously reported a similar profile of PD1 expression in B-CLL. 28 The explanation for that specific PD1+/BTLA+ profile could be related to the pathogenesis of B-CLL, which is considered a monoclonal expansion of antigen-selected B lymphocytes with varying degrees of autospecificity. 34, 35 Up-regulation of inhibitory receptors on CLL precursor cells may result from an attempt by the immune system to prevent autoimmune disorders. To this extent, the simultaneous expression of BTLA and HVEM in CLL cells suggests the triggering of an inefficient autocrine inhibitory loop. Whatever the significance of this PD-1 hi /BTLA hi double positivity, it represents a new flow cytometric parameter that could be used to distinguish B-CLL from other small B-cell proliferations.
Finally, the identification of BTLA expression on TFH cells provides an opportunity to design new therapeutic approaches aiming to trigger the BTLA inhibitory pathway in autoimmune diseases. Similarly, although expression of both BTLA and HVEM by expanding SLL/CLL cells is obviously inefficient in controlling tumor growth, it could be considered a basis for new strategies of targeted immunotherapies.
